AS-703026 (pimasertib) has a clinical activity of phosphorylated extracellular signal-regulated kinase (pERK) inhibition in peripheral blood mononuclear cells in patients with locally advanced/metastatic melanoma, particularly BRAF- and NRAS-mutated tumors at clinically relevant doses in a phase I study [43]. Here, BRAF is linked to metastatic melanoma.